Gerald Dunn
Primary Care · Goodyear, AZNPI 1407543481
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.5% of the total across 160 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 14.1% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,426, 5.1 times the $279 reported in 2023.
Across 160 payments — averaging $18.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$411
- GSK$389
- AbbVie$387
- Lilly USA, LLC$374
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$210
- Astellas Pharma US Inc$173
- plus $976 from 17 others
What the payments were for
- Food & beverage$2,87598%
- Education$452%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 12 | $411 |
| GSK | 20 | $389 |
| AbbVie | 27 | $387 |
| Lilly USA, LLC | 26 | $374 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 14 | $210 |
| Astellas Pharma US Inc | 6 | $173 |
| Novo Nordisk | 14 | $166 |
| Boehringer Ingelheim | 8 | $144 |
| Corcept Therapeutics | 5 | $120 |
| Bayer | 5 | $90 |
| Abbott | 3 | $72 |
| Inspire Medical Systems, Inc. | 3 | $65 |
| Pfizer | 3 | $61 |
| Axsome Therapeutics, Inc. | 3 | $59 |
| Exact Sciences | 2 | $42 |
| Kowa Pharmaceuticals America, Inc. | 2 | $28 |
| Medtronic | 1 | $24 |
| Phadia US Inc. | 1 | $21 |
| Halozyme Inc | 1 | $20 |
| Phathom Pharmaceuticals, Inc. | 1 | $18 |
| Amgen | 1 | $17 |
| Currax Pharmaceuticals LLC | 1 | $16 |
| Merck | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,920 in reported general payments places this provider in the 85th percentile of 151 primary care providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 41 | $44,849 |
| MounjaroTirzepatide | 23 | $24,474 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 29 | $22,049 |
| FarxigaDapagliflozin Propanediol | 13 | $19,753 |
| EliquisApixaban | 12 | $14,242 |
| Humulin RInsulin Regular, Human | 11 | $1,195 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 41 | $817 |
| Rosuvastatin Calcium | 33 | $813 |
| Diclofenac Sodium | 23 | $797 |
| Gabapentin | 37 | $762 |
| Levothyroxine Sodium | 68 | $570 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 23 | $542 |
| Ondansetron OdtOndansetron | 24 | $497 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 36 | $493 |
| Atorvastatin Calcium | 42 | $444 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $166 | $44,84941 claims |
| Lilly USA, LLCMounjaro | $374 | $24,47423 claims |
| GSKTrelegy Ellipta | $389 | $22,04929 claims |
| AstraZenecaFarxiga | $411 | $19,75313 claims |
| PfizerEliquis | $61 | $14,24212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 151 primary care providers in Arizona.
Other primary care in Goodyear
- Angela DavisGoodyear$822
- Trey PowrzanasPhoenix$16K
- Christine Rocks-LopezPhoenix$14K
- Elena KlimovaPhoenix$8K
- Albert VillafaniaPhoenix$8K
- Daniela HaimovPhoenix$8K
- Lea NickolasAvondale$7K
- Neena VargheseSacaton$6K
- Katy DodtQueen Creek$5K
- Mercy GeorgeQueen Creek$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.